Table 1.
Clinical studies on arginine depletion in glioma treatment.
| Disease | Treatment | Clinical phase | No. of patients | Status | Clinical Trials.gov Identifier |
|---|---|---|---|---|---|
| Recurrent high-grade glioma (ASS1-deficient) |
ADI-PEG20 with pemetrexed and cisplatin | Phase I | 10 | Terminated | NCT02029690 |
| Glioblastoma multiforme | ADI-PEG 20 with Radiotherapy and Temozolomide | Phase I | 32 (Estimated) |
Recruiting | NCT04587830 |
| Advanced solid cancers | ADI-PEG 20 with pembrolizumab | Phase I | 33 | Terminated | NCT03254732 |
| High-grade gliomas and others |
rhArg1peg5000 | phase I/II | 64 (Estimated; Children and Young Adults) |
Unknown | NCT03455140 |
| Advanced/Metastatic solid tumors | INCMGA00012 (PD-1 Inhibitor), INCB001158(Arginase Inhibitor), and the combination | Phase I | 18 | Completed | NCT03910530 |
| Advanced/Metastatic solid tumors | INCB001158 with chemotherapy | phase I/II | 149 | Active, not recruiting | NCT03314935 |